Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.
Australia’s first Green Biopharm . Protein-based medicines and vaccines represent the fastest growing sector of the pharmaceutical market, but their production by Australian small and medium enterprises is prohibited by the high infrastructure and operating costs of traditional manufacturing systems. This project aims to develop advanced methods to produce protein-based medicines using a native plant. The power of this technology will be demonstrated by making a biologic anti-parasite treatment, ....Australia’s first Green Biopharm . Protein-based medicines and vaccines represent the fastest growing sector of the pharmaceutical market, but their production by Australian small and medium enterprises is prohibited by the high infrastructure and operating costs of traditional manufacturing systems. This project aims to develop advanced methods to produce protein-based medicines using a native plant. The power of this technology will be demonstrated by making a biologic anti-parasite treatment, as an alternative to outdated chemical treatments. Expected outcomes include a unique scalable technology which will support Australia's sovereign capacity to produce high-value proteins, rapidly, affordably, and at scale, and with less complexity than current plant-based systems. Read moreRead less